These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 35205366)

  • 21. Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies.
    Plowman JN; Matoy EJ; Uppala LV; Draves SB; Watson CJ; Sefranek BA; Stacey ML; Anderson SP; Belshan MA; Blue EE; Huff CD; Fu Y; Stessman HAF
    HGG Adv; 2024 Jul; 5(3):100306. PubMed ID: 38734904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
    Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    Ohmoto A; Yachida S; Morizane C
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
    Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S
    J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
    Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
    JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
    Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
    Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome.
    Gargiulo S; Torrini M; Ollila S; Nasti S; Pastorino L; Cusano R; Bonelli L; Battistuzzi L; Mastracci L; Bruno W; Savarino V; Sciallero S; Borgonovo G; Nyström M; Bianchi-Scarrà G; Mareni C; Ghiorzo P
    Fam Cancer; 2009; 8(4):547-53. PubMed ID: 19728162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
    Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heritable Gastrointestinal Cancer Syndromes.
    Stoffel EM
    Gastroenterol Clin North Am; 2016 Sep; 45(3):509-27. PubMed ID: 27546846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penetrance estimates for
    Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
    J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary cancer syndromes as model systems for chemopreventive agent development.
    Walcott FL; Patel J; Lubet R; Rodriguez L; Calzone KA
    Semin Oncol; 2016 Feb; 43(1):134-145. PubMed ID: 26970132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
    Pennington KP; Walsh T; Lee M; Pennil C; Novetsky AP; Agnew KJ; Thornton A; Garcia R; Mutch D; King MC; Goodfellow P; Swisher EM
    Cancer; 2013 Jan; 119(2):332-8. PubMed ID: 22811390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.
    Goehringer C; Sutter C; Kloor M; Gebert J; Slater EP; Keller M; Treiber I; Ganschow P; Kadmon M; Moog U
    Fam Cancer; 2017 Apr; 16(2):303-309. PubMed ID: 27838800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.